Silo Pharma (SILO)

Executive Summary

Silo Pharma, Inc. (Nasdaq: SILO) is a developmental-stage biopharmaceutical company with a unique dual focus on psychedelic-based therapeutics and cryptocurrency treasury management. The company's pipeline targets underserved CNS conditions, including stress-induced psychiatric disorders, chronic pain, and neurodegenerative diseases. Its lead programs include SPC-15, a novel serotonin receptor modulator for PTSD, and SP-26, a potential treatment for fibromyalgia and chronic pain. Additionally, Silo holds preclinical assets for Alzheimer's disease and multiple sclerosis. The company's cryptocurrency treasury adds a non-traditional dimension, providing alternative liquidity but also introducing volatility risk. Silo Pharma's strategy emphasizes repurposing known compounds with established safety profiles to accelerate development. As a small-cap public company with a market capitalization of approximately $7 million, Silo faces significant funding and execution risks. However, its focus on underserved indications and the growing interest in psychedelic therapies offer potential opportunities. Near-term value drivers include preclinical data readouts and potential advancement into clinical trials. Investors should monitor the company's ability to secure financing and navigate regulatory pathways in a high-risk, high-reward sector.

Upcoming Catalysts (preview)

• Q3 2026Preclinical data release for SP-26 (fibromyalgia/chronic pain)50% success
• Q4 2026IND filing or Phase 1 trial initiation for SPC-15 (PTSD)40% success
• TBDPotential partnership or licensing deal (pipeline or crypto treasury)30% success